Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same author

Asenapine: A Review in Schizophrenia.

CNS drugs·2016
Same author

AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus.

Drugs·2015
Same author

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.

Drugs·2015
Same author

Acamprosate: A Review of Its Use in Alcohol Dependence.

Drugs·2015
Same author

Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain.

Clinical drug investigation·2015

Related Experiment Video

Updated: Jul 17, 2026

Light-Induced Molecular Adsorption of Proteins Using the PRIMO System for Micro-Patterning to Study Cell Responses to Extracellular Matrix Proteins
09:49

Light-Induced Molecular Adsorption of Proteins Using the PRIMO System for Micro-Patterning to Study Cell Responses to Extracellular Matrix Proteins

Published on: October 11, 2019

Limaprost.

Tracy Swainston Harrison1, Greg L Plosker

  • 1Wolters Kluwer Health, Adis, Auckland, New Zealand.

Drugs
|January 11, 2007
PubMed
Summary

Oral limaprost demonstrated efficacy in improving symptoms for patients with lumbar spinal canal stenosis. The drug was well-tolerated, with serious adverse events being rare in clinical trials.

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Vascular Medicine

Background:

  • Limaprost is a prostaglandin E1 analogue and vasodilator.
  • It increases blood flow and inhibits platelet aggregation.
  • Oral limaprost's efficacy was assessed in Japanese adults.

Purpose of the Study:

  • To evaluate the efficacy and safety of oral limaprost.
  • To determine optimal dosage for lumbar spinal canal stenosis.
  • To compare limaprost with ticlopidine for thromboangiitis obliterans.

Main Methods:

  • Three randomized, double-blind, 6-week trials were conducted.
  • One trial involved patients with thromboangiitis obliterans (n=136).
  • Two trials involved patients with lumbar spinal canal stenosis (n=146 in one).

More Related Videos

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
09:26

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

Related Experiment Videos

Last Updated: Jul 17, 2026

Light-Induced Molecular Adsorption of Proteins Using the PRIMO System for Micro-Patterning to Study Cell Responses to Extracellular Matrix Proteins
09:49

Light-Induced Molecular Adsorption of Proteins Using the PRIMO System for Micro-Patterning to Study Cell Responses to Extracellular Matrix Proteins

Published on: October 11, 2019

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
09:26

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

Main Results:

  • Limaprost showed no significant difference vs. ticlopidine for thromboangiitis obliterans.
  • 15 microg/day limaprost was superior to 3 microg/day for lumbar spinal canal stenosis.
  • Limaprost 15 microg/day was well-tolerated with uncommon serious adverse events.

Conclusions:

  • Oral limaprost is a viable treatment option for lumbar spinal canal stenosis.
  • The optimal dosage for lumbar spinal canal stenosis appears to be 15 microg/day.
  • Limaprost was generally safe and well-tolerated in the studied populations.